» Articles » PMID: 16463424

Chronic Periaortitis and HLA-DRB1*03: Another Clue to an Autoimmune Origin

Overview
Journal Arthritis Rheum
Specialty Rheumatology
Date 2006 Feb 8
PMID 16463424
Citations 30
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Patients with chronic periaortitis (CP) often show clinical and laboratory findings of a systemic autoimmune disorder. The aim of the present study was to investigate the role of the HLA system in CP.

Methods: Low-resolution genotyping for HLA-A, HLA-B, and HLA-DRB1 loci and genotyping of TNFA(-238)A/G and TNFA(-308)A/G single nucleotide polymorphisms were performed in 35 consecutive patients with CP and 350 healthy controls.

Results: The HLA-DRB1*03 allele frequency was strikingly higher in patients with CP than in controls (24.28% versus 9.14%; chi(2) = 15.50, P = 0.000084, corrected P [P(corr)] = 0.0012, odds ratio [OR] 3.187, 95% confidence interval [95% CI] 1.74-5.83); the HLA-B*08 allele frequency was also higher in patients than in controls (17.14% versus 6.28%; chi(2)=11.12, P = 0.0008, P(corr) = 0.0269, OR 3.085, 95% CI 1.54-6.16). The A*01 allele frequency was significantly different (P = 0.0463), but the statistical significance was lost after correction for multiple testing (P(corr) = 0.5088). TNFA(-238)A allele and TNFA(-308)A allele frequencies were not significantly different (P = 0.512 and P = 0.445, respectively). Comparison of the main clinical and laboratory findings suggestive of a systemic autoimmune disease (e.g., acute-phase reactants, constitutional symptoms, other autoimmune diseases associated with CP) between the HLA-DRB1*03-positive and the HLA-DRB1*03-negative patients showed that the former group had significantly higher levels of C-reactive protein (P = 0.045) at disease onset, although this difference was not statistically significant after correction for multiple tests (P(corr) = 0.369).

Conclusion: The HLA system plays a role in susceptibility to CP. The strong association between CP and HLA-DRB1*03, an allele linked to a wide range of autoimmune conditions, further supports the view that CP may represent a clinical manifestation of an autoimmune disease.

Citing Articles

Treatment approaches for idiopathic retroperitoneal fibrosis: a systematic review with meta-analysis.

Steimer A, Becker M BMC Rheumatol. 2025; 9(1):12.

PMID: 39910636 PMC: 11800648. DOI: 10.1186/s41927-024-00445-z.


Vascular Involvement of Immunoglobulin G4-Related Disease: A Case Report.

Jamjoom M, Altirkistani B, Alghamdi Y, Alansari A Cureus. 2023; 15(4):e37893.

PMID: 37213955 PMC: 10199732. DOI: 10.7759/cureus.37893.


Combined therapy of prednisone and mTOR inhibitor sirolimus for treating retroperitoneal fibrosis.

Gao H, Liu S, Mai Y, Wang Y, Zhang X, Zheng S Ann Rheum Dis. 2023; 82(5):688-697.

PMID: 36720581 PMC: 10176363. DOI: 10.1136/ard-2022-223736.


Decreased absolute number of peripheral regulatory T cells in patients with idiopathic retroperitoneal fibrosis.

Liu L, Yan H, Wang Y, Xie Y, Jiang L, Zhao J Front Immunol. 2022; 13:1012513.

PMID: 36524110 PMC: 9744965. DOI: 10.3389/fimmu.2022.1012513.


Adolescent IgG4-related retroperitoneal fibrosis with left lower extremity edema as the first symptom: A case report.

Huang M, Yin Z Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2022; 46(12):1437-1441.

PMID: 35232916 PMC: 10930578. DOI: 10.11817/j.issn.1672-7347.2021.200773.